These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 24433001)
1. Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene). Polyzos SA; Singhellakis PN; Naot D; Adamidou F; Malandrinou FC; Anastasilakis AD; Polymerou V; Kita M J Clin Endocrinol Metab; 2014 Mar; 99(3):703-7. PubMed ID: 24433001 [TBL] [Abstract][Full Text] [Related]
2. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease. Grasemann C; Schündeln MM; Hövel M; Schweiger B; Bergmann C; Herrmann R; Wieczorek D; Zabel B; Wieland R; Hauffa BP J Clin Endocrinol Metab; 2013 Aug; 98(8):3121-6. PubMed ID: 23788687 [TBL] [Abstract][Full Text] [Related]
3. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. Whyte MP; Singhellakis PN; Petersen MB; Davies M; Totty WG; Mumm S J Bone Miner Res; 2007 Jun; 22(6):938-46. PubMed ID: 17352649 [TBL] [Abstract][Full Text] [Related]
4. Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation. Saki F; Karamizadeh Z; Nasirabadi S; Mumm S; McAlister WH; Whyte MP J Bone Miner Res; 2013 Jun; 28(6):1501-8. PubMed ID: 23322328 [TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to pamidronate treated effectively with zoledronate in juvenile Paget's disease. Gonc EN; Ozon A; Buyukyilmaz G; Alikasifoglu A; Simsek OP; Kandemir N Osteoporos Int; 2018 Jun; 29(6):1471-1474. PubMed ID: 29502293 [TBL] [Abstract][Full Text] [Related]
6. [Denosumab as the potent therapeutic agent against Paget's disease of bone]. Hirao M; Hashimoto J Clin Calcium; 2011 Aug; 21(8):1231-8. PubMed ID: 21814030 [TBL] [Abstract][Full Text] [Related]
7. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684 [TBL] [Abstract][Full Text] [Related]
8. Novel homozygous mutations in the osteoprotegerin gene TNFRSF11B in two unrelated patients with juvenile Paget's disease. Naot D; Choi A; Musson DS; Simsek Kiper PÖ; Utine GE; Boduroglu K; Peacock M; DiMeglio LA; Cundy T Bone; 2014 Nov; 68():6-10. PubMed ID: 25108083 [TBL] [Abstract][Full Text] [Related]
9. [Cytokines in bone diseases. Osteoprotegerin and juvenile Paget's disease]. Hosogane N; Miyamoto T Clin Calcium; 2010 Oct; 20(10):1540-4. PubMed ID: 20890037 [TBL] [Abstract][Full Text] [Related]
10. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. Abelson A Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324 [TBL] [Abstract][Full Text] [Related]
11. An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. Janssens K; de Vernejoul MC; de Freitas F; Vanhoenacker F; Van Hul W Bone; 2005 Mar; 36(3):542-8. PubMed ID: 15777670 [TBL] [Abstract][Full Text] [Related]
12. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148 [TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin deficiency and juvenile Paget's disease. Whyte MP; Obrecht SE; Finnegan PM; Jones JL; Podgornik MN; McAlister WH; Mumm S N Engl J Med; 2002 Jul; 347(3):175-84. PubMed ID: 12124406 [TBL] [Abstract][Full Text] [Related]
15. Juvenile Paget's Disease: Report of a successful treatment throughout the complete growth of a patient with a missense TNFRSF11B mutation. Prata AR; Saraiva J; Salgado M; Estanqueiro P Joint Bone Spine; 2021 Dec; 88(6):105243. PubMed ID: 34166796 [TBL] [Abstract][Full Text] [Related]
16. Paget's disease of the bone after treatment with Denosumab: a case report. Schwarz P; Rasmussen AQ; Kvist TM; Andersen UB; Jørgensen NR Bone; 2012 May; 50(5):1023-5. PubMed ID: 22586699 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological therapy of Paget's and other metabolic bone diseases. Hosking D Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763 [TBL] [Abstract][Full Text] [Related]